Balance Sheet
Cash Flow Statement
Capital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protalix BioTherapeutics (PLX) Gains from Sales and Divestitures (2020 - 2025)

Protalix BioTherapeutics has reported Gains from Sales and Divestitures over the past 6 years, most recently at $687232.0 for Q4 2025.

  • Quarterly results put Gains from Sales and Divestitures at $687232.0 for Q4 2025, down 30.74% from a year ago — trailing twelve months through Dec 2025 was $687232.0 (down 30.74% YoY), and the annual figure for FY2025 was $687232.0, down 30.74%.
  • Gains from Sales and Divestitures for Q4 2025 was $687232.0 at Protalix BioTherapeutics, up from $52910.0 in the prior quarter.
  • Over the last five years, Gains from Sales and Divestitures for PLX hit a ceiling of $992313.0 in Q4 2024 and a floor of $52910.0 in Q3 2025.
  • Median Gains from Sales and Divestitures over the past 5 years was $588199.0 (2023), compared with a mean of $552368.2.
  • Biggest five-year swings in Gains from Sales and Divestitures: soared 456.0% in 2022 and later tumbled 47.18% in 2023.
  • Protalix BioTherapeutics' Gains from Sales and Divestitures stood at $166553.0 in 2021, then soared by 456.0% to $926035.0 in 2022, then tumbled by 47.18% to $489166.0 in 2023, then surged by 102.86% to $992313.0 in 2024, then tumbled by 30.74% to $687232.0 in 2025.
  • The last three reported values for Gains from Sales and Divestitures were $687232.0 (Q4 2025), $52910.0 (Q3 2025), and $992313.0 (Q4 2024) per Business Quant data.